Nothing Special   »   [go: up one dir, main page]

KR950010888A - 평활근세포 증식 및 재발협착증을 억제하는 방법 - Google Patents

평활근세포 증식 및 재발협착증을 억제하는 방법 Download PDF

Info

Publication number
KR950010888A
KR950010888A KR1019940026034A KR19940026034A KR950010888A KR 950010888 A KR950010888 A KR 950010888A KR 1019940026034 A KR1019940026034 A KR 1019940026034A KR 19940026034 A KR19940026034 A KR 19940026034A KR 950010888 A KR950010888 A KR 950010888A
Authority
KR
South Korea
Prior art keywords
compound
chem
cell proliferation
smooth muscle
muscle cell
Prior art date
Application number
KR1019940026034A
Other languages
English (en)
Inventor
조세프 컬리난 죠오지
팔 싱 쟈이
단리우드
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950010888A publication Critical patent/KR950010888A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 효과량의 하기 일반식(II) 또는 (I)의 화합물, 및 그의 약학적으로 허용가능한 염 및 용매화합물을 치료해야 할 인간 또는 기타 포유동물에게 투여함을 포함하는 평활근세포 증식 및 재발협착증을 억제하는 방법에 관한 것이다.
또는
상기식에서, R1및 R3는 독립적으로 수소, -CH3,
이고 Ar은 임의적으로 치환된 페닐이고,
R4는 수소 또는 -OR1이다. 또한 재발협착증을 억제하는 방법도 제공된다.

Description

평활근세포 증식 및 재발협착증을 억제하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 평활근세포 증식을 억제하는데 사용하기 위한 하기 일반식(I) 또는(Ⅱ)의 화합물 및 그의 약학적으로 허용가능한 염 또는 용매화합물;
    상기식에서, R1및 R3는 독립적으로 수소, -CH3,이고 Ar은 임의적으로 치환된 페닐이고, R2
    R4는 수소 또는 -OR1이다.
  2. 제1항에 있어서, 상기 화합물이 그의 하이드로클로라이드 염인 화합물.
  3. 제1항에 있어서, 상기 화합물이 하기 일반식의 화합물 또는 그의 하이드로클로라이드 염인 화합물.
  4. 재발협착증을 억제하는데 사용하기 위한 하기 일반식(I) 또는(Ⅱ)의 화합물 및 그의 약학적으로 허용가능한 염 및 용매 화합물.
    상기식에서, R1및 R3는 독립적으로 수소, -CH3,이고 Ar은 임의적으로 치환된 페닐이고, R2
    R4는 수소 또는 -OR1이다.
  5. 제4항에 있어서, 상기 화합물이 그의 하이드로클로라이드 염인 화합물.
  6. 제4항에 있어서, 상기 화합물이 하기 일반식의 화합물 또는 그의 하이드로클로라이드 염인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940026034A 1993-10-15 1994-10-12 평활근세포 증식 및 재발협착증을 억제하는 방법 KR950010888A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8/138,296 1993-10-15
US08/138,296 US5457113A (en) 1993-10-15 1993-10-15 Methods for inhibiting vascular smooth muscle cell proliferation and restinosis

Publications (1)

Publication Number Publication Date
KR950010888A true KR950010888A (ko) 1995-05-15

Family

ID=22481390

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940026034A KR950010888A (ko) 1993-10-15 1994-10-12 평활근세포 증식 및 재발협착증을 억제하는 방법

Country Status (20)

Country Link
US (3) US5457113A (ko)
EP (1) EP0652003B1 (ko)
JP (1) JPH07149641A (ko)
KR (1) KR950010888A (ko)
CN (1) CN1053571C (ko)
AT (1) ATE165510T1 (ko)
AU (1) AU670213B2 (ko)
CA (1) CA2118095A1 (ko)
CZ (1) CZ287419B6 (ko)
DE (1) DE69409913T2 (ko)
ES (1) ES2115163T3 (ko)
HU (1) HUT71234A (ko)
IL (1) IL111288A (ko)
NO (1) NO313082B1 (ko)
NZ (1) NZ264675A (ko)
PH (1) PH31263A (ko)
RU (1) RU2154475C2 (ko)
SG (1) SG45280A1 (ko)
TW (1) TW303298B (ko)
ZA (1) ZA948026B (ko)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
JPH08510451A (ja) 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
CN101185759B (zh) * 1993-07-19 2011-05-25 血管技术药物公司 抗血管生长组合物及使用方法
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US7896914B2 (en) 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7846202B2 (en) 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
US6545027B1 (en) 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
CA2178541C (en) * 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US7867275B2 (en) 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
US7550005B2 (en) 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
AU737078C (en) * 1996-05-24 2002-05-02 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
CA2206752A1 (en) 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
US5797887A (en) * 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
US6530951B1 (en) 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US5866561A (en) * 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6984400B2 (en) * 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
JP4898991B2 (ja) 1998-08-20 2012-03-21 クック メディカル テクノロジーズ エルエルシー 被覆付植込式医療装置
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
US7157419B2 (en) * 2000-03-21 2007-01-02 University Of South Florida Growth factor binding molecules
US6506408B1 (en) * 2000-07-13 2003-01-14 Scimed Life Systems, Inc. Implantable or insertable therapeutic agent delivery device
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
IL155107A0 (en) 2000-10-16 2003-10-31 Conor Medsystems Inc Expandable medical device for delivery of beneficial agent
US6964680B2 (en) 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
JP4393870B2 (ja) * 2001-09-24 2010-01-06 ボストン サイエンティフィック リミテッド 薬剤被覆ステントのための最適用量
JP3990972B2 (ja) * 2001-11-20 2007-10-17 有限会社 キック 血管再狭窄防止薬及び該防止薬がコーティングされた血管内埋め込み器具
US20030139469A1 (en) * 2002-01-23 2003-07-24 The Regents Of The University Of California Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
JP4727987B2 (ja) 2002-07-12 2011-07-20 クック インコーポレイテッド コーティングされた医療装置
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
JP5596896B2 (ja) 2003-03-28 2014-09-24 イノヴェイショナル・ホールディングズ・エルエルシー 有益な薬剤の濃度勾配を有する、移植可能な医療装置の形成方法
US7169179B2 (en) 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE4122484A1 (de) * 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
US5457113A (en) 1995-10-10
IL111288A0 (en) 1994-12-29
HUT71234A (en) 1995-11-28
CA2118095A1 (en) 1995-04-16
EP0652003A1 (en) 1995-05-10
ATE165510T1 (de) 1998-05-15
AU7578894A (en) 1995-05-04
US5462937A (en) 1995-10-31
AU670213B2 (en) 1996-07-04
CN1053571C (zh) 2000-06-21
CZ287419B6 (en) 2000-11-15
NZ264675A (en) 1997-07-27
PH31263A (en) 1998-06-18
US5492926A (en) 1996-02-20
RU2154475C2 (ru) 2000-08-20
ES2115163T3 (es) 1998-06-16
SG45280A1 (en) 1998-01-16
CZ253594A3 (en) 1995-05-17
NO943877L (no) 1995-04-18
DE69409913D1 (de) 1998-06-04
HU9402958D0 (en) 1995-02-28
JPH07149641A (ja) 1995-06-13
IL111288A (en) 1999-05-09
DE69409913T2 (de) 1998-09-24
TW303298B (ko) 1997-04-21
ZA948026B (en) 1996-04-15
NO313082B1 (no) 2002-08-12
NO943877D0 (no) 1994-10-13
EP0652003B1 (en) 1998-04-29
CN1105359A (zh) 1995-07-19

Similar Documents

Publication Publication Date Title
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
KR950010893A (ko) 자궁내막증 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950010890A (ko) 폐경기 증후군의 치료방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950016722A (ko) Ldl 산화 및 죽상동맥경화증의 억제 방법
ATE168887T1 (de) Hemmung von dysfunctionalen uterusblutungen
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
DK0662325T3 (da) Inhibering af ovariedysgenese, forsinket pubertet eller sexuel infantilisme
KR950016734A (ko) 성적 조숙증의 억제방법
EA199800015A1 (ru) Способ ингибирования меланомы
KR950016728A (ko) 여성에서 다모증 및 탈모증을 억제하는 방법
KR950016721A (ko) 대식세포 기능의 증가 방법
KR950016736A (ko) 남성 불임증의 억제 방법
EA199800678A1 (ru) Способ ингибирования мышечно-апоневротических фиброматозов (десмоидных опухолей)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application